Life Sciences Tools & Services
CRL swung to a net loss in Q2 FY2026 as a $63.7 million divestiture charge overshadowed a 19.7% increase in operating income, while cost-saving initiatives and a strategic portfolio overhaul lifted margins.
Key risk: High Leverage and Debt Servicing
Debt-to-equity ratio rose to 1.64x as equity declined from losses and share repurchases, while quarterly interest expense remained high at $30.3 million, limiting financial flexibility.
Other Life Sciences Tools & Services companies